¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26
±³À°ÀÏÀÚ : 2023-02-26
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ½ÅÀåÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 160,000¿ø      
ºñ°í BRC (ÀüÀÏ) + ARC (3/26):160,000 ¿ø, BRC (1ÀÏ) + ARC (3/26) 120,000 ¿ø BRC (1ÀÏ): 80,000 ¿ø, ¸¸65¼¼ ÀÌ»ó ȸ¿ø, Çлý:¸éÁ¦      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:00~09:30 Basic renal pathology and evaluation of primary glomerular disease   ±Ç±â¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:30~10:00 An update on the management of IgA nephropathy   °­¼®ÈÖ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:00~10:30 Immunoglobulin- and complement-mediated glomerular diseases with an MPGN pattern of injury  ¹Ú¼±Èñ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:30~11:00 Overview of the pathogenesis and treatment of ANCA-associated GN (ARC ¿¬°è °­ÀÇ)  È«À¯¾Æ(°¡Å縯ÀÇ´ë) 
È޽Ġ02-26  11:00~11:10 Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:10~11:40 How to use SGLT2 inhibitor and GLP-1 receptor agonist in diabetic kidney disease (ARC ¿¬°è °­ÀÇ)  ±æÈ¿¿í(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:40~12:10 Pathophysiology of diabetic kidney disease  ¹®ÁÖ¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 12:10~12:40 Optimal treatment of dyslipidemia in diabetic kidney disease   À¯ÅÂÇö(¿¬¼¼ÀÇ´ë) 
½Ä»ç 02-26  12:40~13:30 Lunch Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 13:30~14:00 Evaluation for resistant hypertension in advanced CKD patients  ÀÌÁ¤È¯(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:00~14:30 Treatment of osteoporosis in CKD  ±èÁ°æ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:30~15:00 Optimal management of anemia: EPO, iron, and new therapeutics  °í°­Áö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:00~15:30 Hypertension management in kidney transplant recipients  Á¤Á¾Ã¶(¼­¿ïÀÇ´ë) 
È޽Ġ02-26  15:30~15:40 Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:40~16:10 HDF vs. expanded hemodialysis (ARC ¿¬°è °­ÀÇ)  ÀÌ¿µ±â(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:10~16:40 Flow related complication of arteriovenous fistula (ARC ¿¬°è °­ÀÇ)  ¹ÚÈƼ®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:40~17:10 How should we change the PD prescription when adequacy targets are not met?  ±Ç¼ø±æ(ÃæºÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ºû°íÀ»Àü³²´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2023-02-26
´ÙÀ½±Û ´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (1ÀÏÂ÷) : 2023-02-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21212 °æ±â Á¦18ȸ ´ëÇѺ¹¸·¾ÏÇÐȸ Çмú ½ÉÆ÷Áö¾ö : 2024-08-31 0 18 2024-07-02
21211 Àü³² 2024³â ´ëÇѹ̼¼¼ö¼úÇÐȸ Ãß°è Microsurgery Workshop : 2024-08-31 0 19 2024-07-02
21210 ¼­¿ï ´ëÇѽŻý¾ÆÇÐȸ Á¦15Â÷ ±³À°¼¼¹Ì³ª : 2024-08-30 0 14 2024-07-02
21209 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À° : 2024-08-27 0 19 2024-07-02
21208 ¼­¿ï 2024³âµµ ´ëÇÑÅëÁõÇÐȸ ¾à¹°Ä¡·á ¿¬¼ö°­Á : 2024-08-25 0 8 2024-07-02
21207 ¼­¿ï °³¿ø 18Áֳ⠱â³ä 2024 °­µ¿°æÈñ´ëÇб³º´¿ø ³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-08-25 0 9 2024-07-02
21206 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ º¹ºÎ& ºñ´¢ ÃÊÀ½ÆÄ °Ë»ç ÀÔ¹®±³À°: °­ÀÇ ¹× ½Ç½À : 2024-08-25 0 8 2024-07-02
21205 ´ë±¸ Á¦3ȸ °è¸í´ëÇб³ µ¿»êº´¿ø ³»°ú ¿¬¼ö°­Á : 2024-08-25 0 13 2024-07-02
21204 °æºÏ Çѱ¹Ãµ½Ä¾Ë·¹¸£±âÇùȸ 2024 Post Graduate Asthma School (2ÀÏÂ÷) : 2024-08-25 0 9 2024-07-02
21203 ¼­¿ï Á¦32ȸ ´ëÇѺñ¸¸°Ç°­ÇÐȸ 2024 Ãß°èÇмú´ëȸ : 2024-08-25 0 11 2024-07-02
21202 ¼­¿ï Á¦14ȸ ¼Ò¾Æ°úÇб³½Ç ¼Ò¾Æ¾Ë·¹¸£±â, È£Èí±âÁúȯ ¿¬¼ö°­Á : 2024-08-25 0 8 2024-07-02
21201 ¼­¿ï ÇѾç´ëÇб³±¸¸®º´¿ø ¼Ò¾Æû¼Ò³â°ú ½Å»ý¾Æ, ¿µÀ¯¾Æ Why & How : 2024-08-24 0 5 2024-07-02
21200 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø º¸¼ö±³À° : 2024-08-24 0 7 2024-07-02
21199 ¼­¿ï ´ëÇѼҾÆÁßȯÀÚÀÇÇÐȸ Á¦ 8ȸ ¼Ò¾Æ±â°èȯ±â ¿öÅ©¼ó : 2024-08-24 0 9 2024-07-02
21198 ¼­¿ï 2024³â ´ëÇѳ»ºÐºñÇÐȸ ´ëÇѼºÈ£¸£¸ó¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-08-24 0 13 2024-07-02
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷